$1.11
-0.04 (-3.48%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where REVB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.NCT06863467Effect of Gemini versus placebo on the incidence of treatment-emergent adverse events.Randomized · Single-masked · Treatment | Phase 1/2 | Completed | Drug: Intravenous Gemini, Intravenous placebo | Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | 40 | 2025-07-22actual | 2025-10-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19